A process for interpreting data on adverse drug events: determining optimal target levels.
The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) primarily accredits health care organizations against broad-based standards of performance. However, it has a role in postmarketing drug surveillance, specifically in terms of how health care organizations accredited by the Joint Commission review and respond to significant adverse drug events (ADEs) that occur in their organization. This paper discusses the role of the Joint Commission in reducing the incidence and severity of ADEs.